Abstract
Recently, BRC has been proposed as a novel agent for the treatment of tall stature in adolescents based on its ability to reduce adult height prediction (HP). Eight boys with a chronological age of 10.3-15.4 yrs (mean 13.3 yrs) were treated for 1 yr with BRC 7.5 mg daily. At the onset of therapy, adult height prediction according to Bayley-Pinneau (HP-BP) was 200.7 to 209.7 cm and according to Tanner Mark II (HP-TWII) 199.0-211.5 cm. After 1 yr of therapy, HP with both methods had decreased in every boy, changing by -4.13±1.86(SD) cm (HP-BP) or -3.35±2.39(SD) cm (HP-TWII), respectively. To substantiate these findings, each patient was pair-matched with a control, an untreated boy with a height above +2SDS and a bone age differing less than 0.5 yr. HP-BP was significantly reduced in patients after 1 yr of BRC compared with their matched controls after 1 yr of follow-up (p less than 0.02). By contrast, differences in HP-TWII were not significant. Because of this discrepancy it is uncertain whether final height in tall boys will really be reduced by treatment with BRC. BRC was kindly provided by Dr. R. Schmidt, Sandoz Ltd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
